Evidence map›Paper›PMID 31552791›Full record

ArticleSmall GTPases2021

LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner

Emma McGrath, Dieter Waschbüsch, Brian M Baker, Amir R Khan

Open access · bronzeAbstract read
In one paragraph

Article in Small GTPases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 75 citations in OpenAlex.

  1. Article
  2. The structural basis for LRRK2's activation and autoinhibition.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Elucidating the molecular interplay between LRRK2 and Rab GTPases.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. ThemedRxiv : the preprint server for health sciences · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Rab32 regulates Golgi structure and cell migration through Protein Kinase A-mediated phosphorylation of Optineurin.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Emma McGrathSchool of Biochemistry and Immunology, Trinity College Dublin , Dublin, Ireland.ORCID 0000-0002-7257-560X
Dieter WaschbüschSchool of Biochemistry and Immunology, Trinity College Dublin , Dublin, Ireland.
Brian M BakerDepartment of Chemistry and Biochemistry, University of Notre Dame , Notre Dame, IN.
Amir R KhanSchool of Biochemistry and Immunology, Trinity College Dublin , Dublin, Ireland.ORCID 0000-0003-1176-6952
Trinity College Dublin · IEUniversity of Notre Dame · US

Funding

Overall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3M
NIGMS NIH HHS P41 GM103403
6 · The paper itself

Abstract

LRRK2 is a multi-domain Ser/Thr kinase that is associated with inherited and sporadic cases of Parkinson's disease. Many mutations linked to disease are associated within a central ROC-COR regulatory region and the subsequent kinase domain, leading to enhanced catalytic activity. The N-terminus of human LRRK2 consists of armadillo repeat motifs (ARMs) followed by ankyrin repeats (ANKs). Recently, Rab GTPases have emerged as key players in LRRK2 function, both as substrates of the kinase, and as regulators of the catalytic activity. Rabs recruit effector proteins

Indexed as

biophysicsleucine-rich repeat kinase 2membrane traffickingRab32 subfamilyRab GTPasesX-ray crystallography

Identifiers

PMID31552791
PMCPMC7849779
OpenAlexW2976101375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.